ONCOSIL MEDICAL LTD - Announcements

1.80%

$1.09

Market Cap $20.51M

Healthcare Biotechnology

OncoSil Medical Ltd is an Australia-based medical device company focused on localized... OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.More

Actinogen Medical (ASX:ACW) reaches 100th participant milestone in Alzheimer’s Disease Trial & confirms interim analysis timeline.

Announcements

Filter Results

All Price Sensitive Only

OSL	Notice of change of substantial holder		11/02/16	140.59KB	Share
OSL	Ceasing to be a substantial holder		11/02/16	1.05MB	Share
OSL	Cleansing Notice & Appendix 3B		10/02/16	373.41KB	Share
OSL	Becoming a substantial holder		09/02/16	121.26KB	Share
OSL	$10 Million Institutional Placement	PRICE SENSITIVE	03/02/16	421.69KB	Share
OSL	Notification of change of Share Registry		29/01/16	84.41KB	Share
OSL	Appendix 4C - Quarterly Cashflow	PRICE SENSITIVE	28/01/16	593.75KB	Share
OSL	Initial Directors interest		25/01/16	191.66KB	Share
OSL	OncoSil Medical Cleansing Notice & Appendix 3B		21/01/16	872.48KB	Share
OSL	Dr Chris Roberts - appointed Non-Executive Director		21/01/16	131.48KB	Share
OSL	Appendix 3B		13/01/16	560.16KB	Share
OSL	Share Option Vesting Conditions Met		07/01/16	333.7KB	Share
OSL	Share Option Vesting Conditions Met		23/12/15	405.62KB	Share
OSL	Appendix 3F updated		23/12/15	28.04KB	Share
OSL	OncoSil Medical appoints Charles Rowland President - USA		15/12/15	127.86KB	Share
OSL	Notice of change of interests of substantial holder		14/12/15	136.17KB	Share
OSL	US FDA Investigational Device Exemption submitted	PRICE SENSITIVE	14/12/15	220.43KB	Share
OSL	ASIC 484 (Section C)		14/12/15	142.38KB	Share
OSL	Appendix 3F		14/12/15	63.12KB	Share
OSL	OncoSil Medical - Reciept of R&D Tax Incentive Refund	PRICE SENSITIVE	27/11/15	98.57KB	Share
OSL	OncoSil Medical Appendix 3C		26/11/15	252.4KB	Share
OSL	OncoSil Medical - results of the 2015 Annual General Meeting		26/11/15	111.64KB	Share
OSL	OncoSil Medical AGM presentation November 26th 2015		26/11/15	1001.51KB	Share
OSL	OncoSil Medical Interview on CE Mark and Growth Plans		26/11/15	101.43KB	Share
OSL	Notice of initial substantial shareholder		23/11/15	1.15MB	Share
OSL	OncoSil Medical's CEO presents at ASX CEO session		17/11/15	822.51KB	Share
OSL	OncoSil AGM Notice of Meeting 2015		10/11/15	526.04KB	Share
OSL	OSL Voting Form		10/11/15	205.67KB	Share
OSL	Release from escrow		09/11/15	106.06KB	Share
OSL	Appendix 4C - Quarterly	PRICE SENSITIVE	29/10/15	89.48KB	Share
OSL	OncoSil Medical appoints new CFO Tom Milicevic		22/10/15	127.36KB	Share
OSL	OncoSil Medical CE Mark Update	PRICE SENSITIVE	12/10/15	101.16KB	Share
OSL	OncoSil Medical cleansing notice and Appendix 3B		08/10/15	248.19KB	Share
OSL	OncoSil strengthens management team		08/10/15	133.54KB	Share
OSL	Van Leeuwenhoeck Institute initiates Research Coverage		01/10/15	102.49KB	Share
OSL	Change of substantial shareholder interests		17/09/15	135.93KB	Share
OSL	EU Fast Track Review for CE Mark confirmed	PRICE SENSITIVE	09/09/15	555.02KB	Share
OSL	2015 Corporate Governance Statement and Appendix 4G		28/08/15	2.81MB	Share
OSL	Appendix 4E and Annual Report to shareholders	PRICE SENSITIVE	28/08/15	592.16KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/15	59.68KB	Share
OSL	OncoSil Medical Investor Update - July 2015		08/07/15	2.49MB	Share
OSL	CMO appointed in lead-up to Commercialisation		04/06/15	217.71KB	Share
OSL	OncoSil Medical - Investor Presentation June 2015		03/06/15	697.9KB	Share
OSL	Prof Pierce Chow Announcement	PRICE SENSITIVE	21/05/15	140.04KB	Share
OSL	OncoSil European Commercialisation On-Track		18/05/15	112.34KB	Share
OSL	Appendix 3B		11/05/15	554.55KB	Share
OSL	Final Director's Interest Notice		11/05/15	215.9KB	Share
OSL	Proactive Investor Presentation May 2015		05/05/15	623.49KB	Share
OSL	OncoSil Medical Investor Presentation announcement		05/05/15	89.61KB	Share
OSL	OncoSil Medical - Director resignation		04/05/15	116.15KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/15	333.22KB	Share
OSL	OncoSil Medical ISO Certification Announcement	PRICE SENSITIVE	27/04/15	129.69KB	Share
OSL	OncoSil HCC Announcement	PRICE SENSITIVE	16/03/15	290.79KB	Share
OSL	Investor Update March 2015		05/03/15	817.88KB	Share
OSL	Half Year Accounts	PRICE SENSITIVE	26/02/15	324.11KB	Share
OSL	Global Registration Plan advances	PRICE SENSITIVE	25/02/15	1.1MB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	27/01/15	243.42KB	Share
OSL	R&D Incentive Approval	PRICE SENSITIVE	16/12/14	309.4KB	Share
OSL	Ceasing to be a substantial holder		09/12/14	71.28KB	Share
OSL	Appendix 3B		08/12/14	628.34KB	Share
OSL	Share Cancellation		01/12/14	108.93KB	Share
OSL	Change of Director's Interest Notice		28/11/14	228.56KB	Share
OSL	Initial Director's Interest Notice		28/11/14	217.59KB	Share
OSL	Director Appointment/Resignation		28/11/14	304.69KB	Share
OSL	Appendix 3B		28/11/14	552.34KB	Share
OSL	Final Director's Interest Notice		28/11/14	267.56KB	Share
OSL	Results of Meeting		28/11/14	123.58KB	Share
OSL	Market Update		28/11/14	459.67KB	Share
OSL	Appendix 3B		24/11/14	545.8KB	Share
OSL	New CEO receives Incentive Loan-Funded Shares		24/11/14	420.54KB	Share
OSL	Appointment of CEO	PRICE SENSITIVE	11/11/14	520.74KB	Share
OSL	Notice of Annual General Meeting/Proxy Form		28/10/14	229.87KB	Share
OSL	Appendix 4C - Quarterly	PRICE SENSITIVE	28/10/14	327.12KB	Share
OSL	OncoSil Medical presentation - October 2014		16/10/14	593.46KB	Share
OSL	Board and senior management restructure	PRICE SENSITIVE	09/09/14	149.19KB	Share
OSL	Appendix 4E	PRICE SENSITIVE	29/08/14	875.07KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/14	323.61KB	Share
OSL	Bioshares investor conference 2014 presentation		18/07/14	638.87KB	Share
OSL	Investor Update July 2014		17/07/14	1.82MB	Share
OSL	GMP manufacturing process finalised for OncoSil Medical	PRICE SENSITIVE	16/07/14	156.72KB	Share
OSL	Ethics Approval Granted for OncoSil in Pancreatic Cancer	PRICE SENSITIVE	15/07/14	151.94KB	Share
OSL	Appendix 3B		26/05/14	477.25KB	Share
OSL	Investor update		08/05/14	2.64MB	Share
OSL	Results of Meeting		29/04/14	321.13KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	22/04/14	251.19KB	Share
OSL	Release of Shares from Voluntary Escrow		17/04/14	310.67KB	Share
OSL	OncoSil Medical Ltd - Investor Update		11/04/14	1.29MB	Share
OSL	Change of Director's Interest Notice		20/03/14	222.62KB	Share
OSL	Notice of Extraordinary General Meeting/Proxy Form		20/03/14	496.69KB	Share
OSL	Amended - Response to ASX Appendix 3X Query		19/03/14	339.08KB	Share
OSL	Undertakings to the ASX		18/03/14	271.51KB	Share
OSL	Response to ASX Appendix 3X Query		17/03/14	310.63KB	Share
OSL	OncoSil Medical commences Pivotal Trial	PRICE SENSITIVE	17/03/14	441.32KB	Share
OSL	Initial Director's Interest Notice		11/03/14	85.43KB	Share
OSL	Appendix 4D and Half Year Report	PRICE SENSITIVE	27/02/14	957.36KB	Share
OSL	OncoSil Medical appoints Lawrence Gozlan as Director		27/02/14	395.92KB	Share
OSL	OncoSil Medical appoints Peter Casey joint Company Secretary		27/02/14	397.84KB	Share
OSL	Investor Presentation		25/02/14	1.39MB	Share
OSL	Oncosil Change of Address		20/02/14	267.61KB	Share
OSL	Oncosil's next generation delivery platform	PRICE SENSITIVE	20/02/14	405.15KB	Share

OSL Notice of change of substantial holder
11/02/16		140.59KB	Share
OSL Ceasing to be a substantial holder
11/02/16		1.05MB	Share
OSL Cleansing Notice & Appendix 3B
10/02/16		373.41KB	Share
OSL Becoming a substantial holder
09/02/16		121.26KB	Share
OSL $10 Million Institutional Placement
03/02/16	PRICE SENSITIVE	421.69KB	Share
OSL Notification of change of Share Registry
29/01/16		84.41KB	Share
OSL Appendix 4C - Quarterly Cashflow
28/01/16	PRICE SENSITIVE	593.75KB	Share
OSL Initial Directors interest
25/01/16		191.66KB	Share
OSL OncoSil Medical Cleansing Notice & Appendix 3B
21/01/16		872.48KB	Share
OSL Dr Chris Roberts - appointed Non-Executive Director
21/01/16		131.48KB	Share
OSL Appendix 3B
13/01/16		560.16KB	Share
OSL Share Option Vesting Conditions Met
07/01/16		333.7KB	Share
OSL Share Option Vesting Conditions Met
23/12/15		405.62KB	Share
OSL Appendix 3F updated
23/12/15		28.04KB	Share
OSL OncoSil Medical appoints Charles Rowland President - USA
15/12/15		127.86KB	Share
OSL Notice of change of interests of substantial holder
14/12/15		136.17KB	Share
OSL US FDA Investigational Device Exemption submitted
14/12/15	PRICE SENSITIVE	220.43KB	Share
OSL ASIC 484 (Section C)
14/12/15		142.38KB	Share
OSL Appendix 3F
14/12/15		63.12KB	Share
OSL OncoSil Medical - Reciept of R&D Tax Incentive Refund
27/11/15	PRICE SENSITIVE	98.57KB	Share
OSL OncoSil Medical Appendix 3C
26/11/15		252.4KB	Share
OSL OncoSil Medical - results of the 2015 Annual General Meeting
26/11/15		111.64KB	Share
OSL OncoSil Medical AGM presentation November 26th 2015
26/11/15		1001.51KB	Share
OSL OncoSil Medical Interview on CE Mark and Growth Plans
26/11/15		101.43KB	Share
OSL Notice of initial substantial shareholder
23/11/15		1.15MB	Share
OSL OncoSil Medical's CEO presents at ASX CEO session
17/11/15		822.51KB	Share
OSL OncoSil AGM Notice of Meeting 2015
10/11/15		526.04KB	Share
OSL OSL Voting Form
10/11/15		205.67KB	Share
OSL Release from escrow
09/11/15		106.06KB	Share
OSL Appendix 4C - Quarterly
29/10/15	PRICE SENSITIVE	89.48KB	Share
OSL OncoSil Medical appoints new CFO Tom Milicevic
22/10/15		127.36KB	Share
OSL OncoSil Medical CE Mark Update
12/10/15	PRICE SENSITIVE	101.16KB	Share
OSL OncoSil Medical cleansing notice and Appendix 3B
08/10/15		248.19KB	Share
OSL OncoSil strengthens management team
08/10/15		133.54KB	Share
OSL Van Leeuwenhoeck Institute initiates Research Coverage
01/10/15		102.49KB	Share
OSL Change of substantial shareholder interests
17/09/15		135.93KB	Share
OSL EU Fast Track Review for CE Mark confirmed
09/09/15	PRICE SENSITIVE	555.02KB	Share
OSL 2015 Corporate Governance Statement and Appendix 4G
28/08/15		2.81MB	Share
OSL Appendix 4E and Annual Report to shareholders
28/08/15	PRICE SENSITIVE	592.16KB	Share
OSL Appendix 4C - quarterly
27/07/15	PRICE SENSITIVE	59.68KB	Share
OSL OncoSil Medical Investor Update - July 2015
08/07/15		2.49MB	Share
OSL CMO appointed in lead-up to Commercialisation
04/06/15		217.71KB	Share
OSL OncoSil Medical - Investor Presentation June 2015
03/06/15		697.9KB	Share
OSL Prof Pierce Chow Announcement
21/05/15	PRICE SENSITIVE	140.04KB	Share
OSL OncoSil European Commercialisation On-Track
18/05/15		112.34KB	Share
OSL Appendix 3B
11/05/15		554.55KB	Share
OSL Final Director's Interest Notice
11/05/15		215.9KB	Share
OSL Proactive Investor Presentation May 2015
05/05/15		623.49KB	Share
OSL OncoSil Medical Investor Presentation announcement
05/05/15		89.61KB	Share
OSL OncoSil Medical - Director resignation
04/05/15		116.15KB	Share
OSL Appendix 4C - quarterly
28/04/15	PRICE SENSITIVE	333.22KB	Share
OSL OncoSil Medical ISO Certification Announcement
27/04/15	PRICE SENSITIVE	129.69KB	Share
OSL OncoSil HCC Announcement
16/03/15	PRICE SENSITIVE	290.79KB	Share
OSL Investor Update March 2015
05/03/15		817.88KB	Share
OSL Half Year Accounts
26/02/15	PRICE SENSITIVE	324.11KB	Share
OSL Global Registration Plan advances
25/02/15	PRICE SENSITIVE	1.1MB	Share
OSL Appendix 4C - quarterly
27/01/15	PRICE SENSITIVE	243.42KB	Share
OSL R&D Incentive Approval
16/12/14	PRICE SENSITIVE	309.4KB	Share
OSL Ceasing to be a substantial holder
09/12/14		71.28KB	Share
OSL Appendix 3B
08/12/14		628.34KB	Share
OSL Share Cancellation
01/12/14		108.93KB	Share
OSL Change of Director's Interest Notice
28/11/14		228.56KB	Share
OSL Initial Director's Interest Notice
28/11/14		217.59KB	Share
OSL Director Appointment/Resignation
28/11/14		304.69KB	Share
OSL Appendix 3B
28/11/14		552.34KB	Share
OSL Final Director's Interest Notice
28/11/14		267.56KB	Share
OSL Results of Meeting
28/11/14		123.58KB	Share
OSL Market Update
28/11/14		459.67KB	Share
OSL Appendix 3B
24/11/14		545.8KB	Share
OSL New CEO receives Incentive Loan-Funded Shares
24/11/14		420.54KB	Share
OSL Appointment of CEO
11/11/14	PRICE SENSITIVE	520.74KB	Share
OSL Notice of Annual General Meeting/Proxy Form
28/10/14		229.87KB	Share
OSL Appendix 4C - Quarterly
28/10/14	PRICE SENSITIVE	327.12KB	Share
OSL OncoSil Medical presentation - October 2014
16/10/14		593.46KB	Share
OSL Board and senior management restructure
09/09/14	PRICE SENSITIVE	149.19KB	Share
OSL Appendix 4E
29/08/14	PRICE SENSITIVE	875.07KB	Share
OSL Appendix 4C - quarterly
31/07/14	PRICE SENSITIVE	323.61KB	Share
OSL Bioshares investor conference 2014 presentation
18/07/14		638.87KB	Share
OSL Investor Update July 2014
17/07/14		1.82MB	Share
OSL GMP manufacturing process finalised for OncoSil Medical
16/07/14	PRICE SENSITIVE	156.72KB	Share
OSL Ethics Approval Granted for OncoSil in Pancreatic Cancer
15/07/14	PRICE SENSITIVE	151.94KB	Share
OSLAppendix 3B
26/05/14		477.25KB	Share
OSLInvestor update
08/05/14		2.64MB	Share
OSLResults of Meeting
29/04/14		321.13KB	Share
OSLAppendix 4C - quarterly
22/04/14	PRICE SENSITIVE	251.19KB	Share
OSLRelease of Shares from Voluntary Escrow
17/04/14		310.67KB	Share
OSLOncoSil Medical Ltd - Investor Update
11/04/14		1.29MB	Share
OSLChange of Director's Interest Notice
20/03/14		222.62KB	Share
OSLNotice of Extraordinary General Meeting/Proxy Form
20/03/14		496.69KB	Share
OSLAmended - Response to ASX Appendix 3X Query
19/03/14		339.08KB	Share
OSLUndertakings to the ASX
18/03/14		271.51KB	Share
OSLResponse to ASX Appendix 3X Query
17/03/14		310.63KB	Share
OSLOncoSil Medical commences Pivotal Trial
17/03/14	PRICE SENSITIVE	441.32KB	Share
OSLInitial Director's Interest Notice
11/03/14		85.43KB	Share
OSLAppendix 4D and Half Year Report
27/02/14	PRICE SENSITIVE	957.36KB	Share
OSLOncoSil Medical appoints Lawrence Gozlan as Director
27/02/14		395.92KB	Share
OSLOncoSil Medical appoints Peter Casey joint Company Secretary
27/02/14		397.84KB	Share
OSLInvestor Presentation
25/02/14		1.39MB	Share
OSLOncosil Change of Address
20/02/14		267.61KB	Share
OSLOncosil's next generation delivery platform
20/02/14	PRICE SENSITIVE	405.15KB	Share

REFRESH

First 3 4 5 6 7

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.09		Change -0.020(1.80%)		Mkt cap ! $20.51M

Open	High	Low	Value	Volume
$1.11	$1.12	$1.08	$19.98K	18.08K

Buyers (Bids)

No.	Vol.	Price($)
3	3196	$1.08

Sellers (Offers)

Price($)	Vol.	No.
$1.09	3598	1

View Market Depth

No.	Vol.	Price($)
3	3196	1.080
2	2011	1.070
1	77	1.065
3	5442	1.060
2	2654	1.050

Price($)	Vol.	No.
1.090	3598	1
1.115	1875	1
1.140	5000	1
1.145	5000	1
1.150	6938	1

Last trade - 16.10pm 08/08/2025 (20 minute delay)

OSL (ASX) Chart

ONCOSIL MEDICAL LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories